AFAP1L2 Rabbit anti-Human, Mouse, Rat, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA520770
A suggested positive control is mouse liver tissue lysate. PA5-20770 can be used with blocking peptide PEP-0884.AFAP1L2, also known as XB130, is structurally similar to actin-filament-associated protein (AFAP), containing several SH2- and SH3-binding motifs, two pleckstrin homology domains, a coiled-coil region, and many potential phosphorylation sites. It interacts with and is phosphorylated by c-Src tyrosine kinase. Suppression of AFAP1L2 via siRNA reduced Src activity, IL-8 production, EGF-induced phosphorylation of Akt and GSK3beta, and altered cell cycles in human lung epithelial cells suggesting that AFAP1L2 plays a role as an adaptor in the regulation of Src signal transduction and multiple cellular functions. Recent experiments have shown that AFAP1L2 is highly expressed in thyroid and is the substrate RET/PTC kinase, a thyroid-specific kinase that plays a pathogenic role in papillary thyroid cancer. Down-regulation of AFAP1L2 in these cancer cells reduced Akt activity, inhibiting cell-cycle progression and cancer cell survival in suspension, indicating that AFAP1L2 may be a valuable target in thyroid cancer therapy. At least four isoforms of AFAP1L2 are known to exist.
|A 15 amino acid peptide near the carboxy terminus of human AFAP1L2.|
|Antigen affinity chromatography|
|Human, Mouse, Rat|
|Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Western Blot|
|PBS with 0.02% sodium azide|
|KIAA1914, XB130; AFAP1-like protein 2; CTB-1144G6.4; actin filament-associated protein 1-like 2|
|Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|226250, 292130, 84632|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok